SS
COYA icon

SBI Securities’s Coya Therapeutics COYA Stock Holding History

SBI Securities’s Portfolio COYA Stock Details COYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.8K Sell
820
-101
-11% -$468 ﹤0.01% 2195
2026
Q1 		$3.63K Hold
921
– – ﹤0.01% 2168
2025
Q4 		$5.34K Sell
921
-1
-0.1% -$6 ﹤0.01% 1989
2025
Q3 		$5.25K Buy
922
+1
+0.1% +$6 ﹤0.01% 2022
2025
Q2 		$5.3K Buy
921
+10
+1% +$58 ﹤0.01% 1963
2025
Q1 		$5.89K Buy
911
+150
+20% +$950 ﹤0.01% 1834
2024
Q4 		$4.36K Buy
+761
New +$5.18K ﹤0.01% 1975

Other funds holding COYA

PMG
Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return
GIA
GHP Investment Advisors Denver, Colorado $2.72B AUM 27.58% 1-Year Est. Return
BL
BFSG LLC Irvine, California $1.13B AUM 29.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.84B AUM 28.81% 1-Year Est. Return
TCM
Triumph Capital Management Denver, Colorado $552M AUM 20.75% 1-Year Est. Return

SBI Securities's COYA Position: Q2 2026 in Review

SBI Securities reduced its Coya Therapeutics (COYA) stake by 11% in Q2 2026, selling an estimated $468 and leaving 820 shares worth $4.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2195.

SBI Securities first reported a position in COYA in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.89K in Q1 2025. 7 funds tracked by Wall St. Rank hold COYA as of Q2 2026.

  • SBI Securities held 820 shares of Coya Therapeutics worth $4.8K as of Q2 2026.
  • SBI Securities sold 101 Coya Therapeutics shares in Q2 2026, an estimated $468.
  • Coya Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2195 holding.
  • SBI Securities first reported a position in Coya Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Coya Therapeutics position peaked at $5.89K in Q1 2025.
  • 7 funds tracked by Wall St. Rank held Coya Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.